Anthropic Launches Claude Science: AI Platform for Drug Discovery and Life Sciences
English summary
On June 30, 2026, Anthropic launched Claude Science, a life-sciences AI platform integrating biology-specialized Claude Opus 4.6 and 4.8 models, a physical wet lab for experimental data feedback, and the acquisition of startup CoefficientBio. The initiative aims to slash overall life-science R&D cycles to one-tenth. Training on biological data is challenging because there is often no single ground-truth answer; the wet lab enables closed-loop model improvement. The platform has attracted capital inflows, with Amazon evaluating pricing, while Anthropic reports annualized revenue of $30 billion and is developing safety classifiers to mitigate dual-use risks.
Chinese summary
2026年6月30日，Anthropic发布生命科学AI平台Claude Science，整合了经生物数据专项训练的Claude Opus 4.6及4.8模型、自主湿实验室生成实验闭环反馈，并收购初创公司CoefficientBio。公司目标是将整体研发周期缩短至原来的十分之一。生物学数据缺少绝对标准答案，训练难度极高，自建湿实验室通过真实数据实现模型迭代。平台已吸引资本涌入，亚马逊正评估定价，公司年化营收达300亿美元，并部署恶意意图分类器以应对双重用途安全风险。
Key points
Anthropic launched Claude Science, a dedicated life-science AI platform built on biology-trained Claude Opus 4.6 and 4.8 models, an in-house wet lab, and the acquisition of CoefficientBio.
平台整合生物专项Claude模型（Opus 4.6/4.8）、自建湿实验室和收购CoefficientBio三部分能力。
The company targets a 10x reduction in life-science R&D timelines but acknowledges that biological data lacks clear ground truth, making model training uniquely difficult.
目标将研发周期压缩至十分之一，但面临生物数据无绝对标准答案的核心训练难题。
Xaira Therapeutics notes the industry has moved from proof-of-concept to early industrialization, but 'one-click drug design' remains unrealistic in the near term.
行业已从概念验证转入早期工业化，但短期内“一键设计新药”仍不现实。
Capital is pouring in: Amazon is evaluating pricing for the platform, and Anthropic's annualized revenue has reached $30 billion.
资本持续涌入，亚马逊正评估平台定价，Anthropic年化营收已达300亿美元。
To address dual-use risks, Anthropic is building classifiers to detect malicious intents and developing stringent access controls.
为应对双重用途风险，Anthropic正构建恶意意图分类器并开发严格访问控制机制。